Esperion Therapeutis.Inc. buy marge
Summary
This prediction ended on 20.12.18 with a price of €39.95. Massive losses of -43.06% were the result for the BUY prediction by marge. marge has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Esperion Therapeutis.Inc. | -4.942% | -4.942% | 101.176% | 42.838% |
| iShares Core DAX® | -1,42 % | 8,92 % | 7,31 % | 49,21 % |
| iShares Nasdaq 100 | 3,27 % | 16,28 % | 36,65 % | 97,34 % |
| iShares Nikkei 225® | 1,75 % | 16,24 % | 46,60 % | 64,98 % |
| iShares S&P 500 | 1,45 % | 10,91 % | 27,17 % | 68,77 % |
Comments by marge for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
marge stimmt der Buy-Einschätzung von Maxi-Scalibusa zu
marge stimmt am 07.03.2018 der Buy-Einschätzung von Maxi-Scalibusa mit dem Kursziel 231,5$ zu.
Überschrift: Hot Stock